On the factors modulating the effect of statins on malignant cell proliferation

Cancer Investigation

Volumn 25, Issue 5, 2007, Pages 279-284

  Bessler, Hanna ^a,c   Salman, Hertzel ^b,c   Bergman, Michael ^b,c   Djaldetti, Meir ^a,c,d  

^a Hematology and Immunology Research Laboratory   (Israel)

^b Tel Aviv University ^*  (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; Cell proliferation; Malignant cell lines; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL TYPE; HYDROPHOBICITY; PRIORITY JOURNAL; RAJI CELL;

ANNEXIN A5; CELL DIVISION; CELL LINE, TUMOR; DNA FRAGMENTATION; DNA, NEOPLASM; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; K562 CELLS; KINETICS; LOVASTATIN; PRAVASTATIN; PYRROLES; SIMVASTATIN;

EID: 34547544674     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701208535     Document Type: Article

References (33)

1. Farnier, M.; Davignon, J. Current and future treatment of hyperlipidemia: the role of statins. Am. J. Cardiol. 1998, 82(43), 3J-10J.
2. Denoyelle, C.; Vasse, M.; Körner, M.; Mishal, Z.; Ganné, F.; et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the intensiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001, 22(8), 1139-1148.
3. Shovman, O.; Levy, Y.; Gilburd, B.; Shoenfeld, Y. Antiinflammatory and immunomodulatory properties of statins. Immunol. Res. 2002, 25(3), 271-285.
4. Li, S.; Koller, R.; Baghestanian, M.; Ghannadan, M.; Minar, E.; et al. Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils. Eur. J. Clin. Pharmacol. 2003, 59(7), 507-516.
5. Danesh, F.R.; Anel, R.l.; Zeng, L.; Lomasney, J.; Sahai, A.; Kanwar, Y.S. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch. Immunol. Ther. Exp. (Warsz) 2003, 51(3), 139-148.
6. Cafforio, P.; Dammacco, F.; Gernone, A.; Silvestris, F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005, 26(5), 883-891.
7. Davignon, J.; Mabile, L. Mechanisms of action of statins and their pleiotropic effects. Ann. Endocrinol. (Paris) 2001, 62(1 Pt. 2), 101-112.
8. Sun, D.; Fernandes, G. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell Immunol. 2003, 223(1), 52-63.
9. Li, H.; Li, X.; Duan, K.; Li, C. Inhibition of lovastatin on proliferation and expression of proinflammatory cytokines in cultured glomerular mesengial cells. Clin. Med. J. (Engl.) 2003, 116(9), 1366-1369.
10. Matsumoto, M.; Einhaus, D.; Gold, E.S.; Aderem, A. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J. Immunol. 2004, 172(12), 7377-7384.
11. Splichal, J.E.; Stam, J.A.; Ornstein, D.L. The statins: multifunctional antithrombotic and antineoplastic drugs. Semin. Thromb. Hemost. 2003, 29(3), 259-274.
12. Etminan, M.; Gill, S.; Samii, A. The role of lipid-lower drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003, 23(6), 726-730.
13. Friis, S.; Poulsen, A.H.; Johnsen, S.P.; McLaughlin, J.K.; Fryzek, J.P.; Dalton, S.O.; Sorenson, H.T.; Olsen, J.H. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 2005, 114(4), 643-647.
14. Graaf, M.R.; Beiderbeck, A.B.; Egberts, A.C.; Richel, D.J.; Guchelaar, H.J. The risk of cancer in users of statins. J. Clin. Oncol. 2004, 22(12), 2388-2394.
15. Graaf, M.R.; Richel, D.J.; van Noorden, C.J.; Guchelaar, H.J. Effect of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 2004, 30(7), 609-641.
16. Sleijfer, S.; van der Gaast, A.; Planting, A.S.; Stoter, G.; Verweij, J. The potential of statins as part of anti-cancer treatment. Eur. J. Cancer 2005, 41(4), 516-522.
17. Kozar, K.; Kaminski, R.; Legat, M.; Kopec, M.; Nowis, D.; Skierski, J.S.; Koronkiewicz, M.; Jakobisiak, M.; Golab, J. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int. J. Oncol. 2004, 24(5), 1149-1157.
18. Jakobisiak, M.; Golap, J. Potential antitumor effect of statins (Review). Int. J. Oncol. 2003, 23(4), 1055-1069.
19. Kaye, J.A.; Jick, H. Statin use and cancer risk in the General Practice Research Database. Br. J. Cancer 2004, 90(3), 635-637.
20. Hawk, E.; Viner, J.L. Statins and cancer-beyond the "one drug, one disease" model. N. Eng. J. Med. 2005, 352(21), 2238-2239.
21. Duke, R.C; Cohen, J.J. (1992) Morphological and biochemical assays of apoptosis. In Coligan, J.E.; Kruisbeek, A.M.; Marguilies, D.H.; Shevach, E.M.; Strober, W. (Eds), Current Protocols in Immunology, Green/Wiley, New York, 1992, Suppl. 3, pp. 3.17.1 and 17.16.
22. Seeger, H.; Wallwiener, D.; Mueck, A.O. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp. Clin. Endocrinol. Diabetes 2003, 111(1), 47-48.
23. Collisson, E.A.; Kleer, C.; Wu, M.; De, A.; Gambhir, S.S.; Merajver, S.D.; Kolodney, M.S. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer. Ther. 2003, 2(10), 941-948.
24. Cauley, J.A.; Zmuda, J.M.; Lui, L.Y.; Hillier, T.A.; Ness, R.B.; Stone, K.L.; Cummings, S.R.; Bauer, D.C. Lipid-lowering drug use and breast cancer in older women: a prospective analysis. Womens Health (Larchmt.) 2003, 12(8), 749-756.
25. Muck, A.O.; Seeger, H.; Wallwiener, D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int. J. Clin. Pharmacol. Ther. 2004, 42(12), 695-700.
26. Poynter, J.N.; Gruber, S.B.; Higgins, P.D.; Almog, R.; Bonner, J.D.; et al. Statins and the risk of colorectal cancer. N. Eng. J. Med. 2005, 352(21), 2238-2239.
27. Paragh, G.; Foris, G.; Paragh, G. Jr.; Serez, I.; Karanyi, Z.; et al. Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats. Cancer Lett. 2005, 222(1), 17-22.
28. Narisawa, T.; Fukaura, Y.; Terada, K.; Umezawa, A.; Tanida, N.; Yazawa, K.; Ishikawa, C. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994, 15(9), 2045-2048.
29. Dale, K.M.; Coleman, C.I.; Henyan, N.N.; Kluger, J.; White, C.M. Statins and cancer risk: a meta-analysis. J.A.M.A. 2006, 295(1), 74-80.
30. Shepherd, J.; Blauw, G.J.; Murphy, M.B.; et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER); a randomised controlled trial. Lancet 2002, 360(9346), 1623-1630.
31. Kaushal, V.; Kohli, M.; Mehta, P.; Mehta, J.L. Potential anticancer effects of statins: fact or fiction? Endothelium 2003, 10(1), 49-58.
32. Ukomadu, C.; Dutta, A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol. Chem. 2003, 278(44), 43586-43594.
33. Newman, A.; Clutterbuck, R.D.; Powless, R.L.; Catovsky, D.; Millar, J coenzyme A (HMG-CoA) reductase in.L. A comparison of the effect of the 3-hydroxy-3-methylglutarylhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk. Lymphoma 1997, 24(5-6), 533-537.